A practical guide to Bayesian group sequential designs†
Abstract
Bayesian approaches to the monitoring of group sequential designs have two main advantages compared with classical group sequential designs: first, they facilitate implementation of interim success and futility criteria that are tailored to the subsequent decision making, and second, they allow inclusion of prior information on the treatment difference and on the control group. A general class of Bayesian group sequential designs is presented, where multiple criteria based on the posterior distribution can be defined to reflect clinically meaningful decision criteria on whether to stop or continue the trial at the interim analyses. To evaluate the frequentist operating characteristics of these designs, both simulation methods and numerical integration methods are proposed, as implemented in the corresponding R package gsbDesign. Normal approximations are used to allow fast calculation of these characteristics for various endpoints. The practical implementation of the approach is illustrated with several clinical trial examples from different phases of drug development, with various endpoints, and informative priors. Copyright © 2013 John Wiley & Sons, Ltd.
Citing Literature
Number of times cited according to CrossRef: 25
- Nigel Stallard, Susan Todd, Elizabeth G. Ryan, Simon Gates, Comparison of Bayesian and frequentist group-sequential clinical trial designs, BMC Medical Research Methodology, 10.1186/s12874-019-0892-8, 20, 1, (2020).
- Abha Maheshwari, Jemma Healey, Siladitya Bhattacharya, Kevin Cooper, Lucky Saraswat, Andrew W Horne, Jane Daniels, Suzanne Breeman, Kate Brian, Gwenda Burns, Jemma Hudson, Katie Gillies, Surgery for women with endometrioma prior to in vitro fertilisation: proposal for a feasible multicentre randomised clinical trial in the UK, Human Reproduction Open, 10.1093/hropen/hoaa012, 2020, 3, (2020).
- Munyaradzi Dimairo, Philip Pallmann, James Wason, Susan Todd, Thomas Jaki, Steven A. Julious, Adrian P. Mander, Christopher J. Weir, Franz Koenig, Marc K. Walton, Jon P. Nicholl, Elizabeth Coates, Katie Biggs, Toshimitsu Hamasaki, Michael A. Proschan, John A. Scott, Yuki Ando, Daniel Hind, Douglas G. Altman, The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design, Trials, 10.1186/s13063-020-04334-x, 21, 1, (2020).
- Munyaradzi Dimairo, Philip Pallmann, James Wason, Susan Todd, Thomas Jaki, Steven A Julious, Adrian P Mander, Christopher J Weir, Franz Koenig, Marc K Walton, Jon P Nicholl, Elizabeth Coates, Katie Biggs, Toshimitsu Hamasaki, Michael A Proschan, John A Scott, Yuki Ando, Daniel Hind, Douglas G Altman, The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design, BMJ, 10.1136/bmj.m115, (m115), (2020).
- Marcus Bendtsen, The P value line dance: when does the music stop? (Preprint), Journal of Medical Internet Research, 10.2196/21345, (2020).
- Nigel Stallard, Lisa Hampson, Norbert Benda, Werner Brannath, Thomas Burnett, Tim Friede, Peter K. Kimani, Franz Koenig, Johannes Krisam, Pavel Mozgunov, Martin Posch, James Wason, Gernot Wassmer, John Whitehead, S. Faye Williamson, Sarah Zohar, Thomas Jaki, Efficient adaptive designs for clinical trials of interventions for COVID-19, Statistics in Biopharmaceutical Research, 10.1080/19466315.2020.1790415, (1-26), (2020).
- Heinz Schmidli, Dieter A. Häring, Marius Thomas, Adrian Cassidy, Sebastian Weber, Frank Bretz, Beyond Randomized Clinical Trials: Use of External Controls, Clinical Pharmacology & Therapeutics, 10.1002/cpt.1723, 107, 4, (806-816), (2019).
- Heinz Schmidli, Bayesian Reduced Rank Regression for Classification, Applications in Statistical Computing, 10.1007/978-3-030-25147-5_2, (19-30), (2019).
- Naoki Isogawa, Kentaro Takeda, Kazushi Maruo, Takashi Daimon, A Comparison Between a Meta-analytic Approach and Power Prior Approach to Using Historical Control Information in Clinical Trials With Binary Endpoints, Therapeutic Innovation & Regulatory Science, 10.1177/2168479019862531, (216847901986253), (2019).
- TB Brakenhoff, KCB Roes, S Nikolakopoulos, Bayesian sample size re-estimation using power priors, Statistical Methods in Medical Research, 10.1177/0962280218772315, 28, 6, (1664-1675), (2018).
- Bo Huang, Enayet Talukder, Lixin Han, Pei-Fen Kuan, Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2018.1489400, 29, 1, (189-202), (2018).
- Masashi Shimura, Kazushi Maruo, Masahiko Gosho, Conditional estimation using prior information in 2‐stage group sequential designs assuming asymptotic normality when the trial terminated early, Pharmaceutical Statistics, 10.1002/pst.1859, 17, 5, (400-413), (2018).
- Philip Pallmann, Alun W. Bedding, Babak Choodari-Oskooei, Munyaradzi Dimairo, Laura Flight, Lisa V. Hampson, Jane Holmes, Adrian P. Mander, Lang’o Odondi, Matthew R. Sydes, Sofía S. Villar, James M. S. Wason, Christopher J. Weir, Graham M. Wheeler, Christina Yap, Thomas Jaki, Adaptive designs in clinical trials: why use them, and how to run and report them, BMC Medicine, 10.1186/s12916-018-1017-7, 16, 1, (2018).
- Satrajit Roychoudhury, Nicolas Scheuer, Beat Neuenschwander, Beyond p -values: A phase II dual-criterion design with statistical significance and clinical relevance , Clinical Trials, 10.1177/1740774518770661, 15, 5, (452-461), (2018).
- Tobias Mütze, Ekkehard Glimm, Heinz Schmidli, Tim Friede, Group sequential designs for negative binomial outcomes, Statistical Methods in Medical Research, 10.1177/0962280218773115, (096228021877311), (2018).
- Tobias Mütze, Heinz Schmidli, Tim Friede, Sample size re‐estimation incorporating prior information on a nuisance parameter, Pharmaceutical Statistics, 10.1002/pst.1837, 17, 2, (126-143), (2017).
- Guosheng Yin, Chi Kin Lam, Haolun Shi, Bayesian randomized clinical trials: From fixed to adaptive design, Contemporary Clinical Trials, 10.1016/j.cct.2017.04.010, 59, (77-86), (2017).
- Heinz Schmidli, Beat Neuenschwander, Tim Friede, Meta-analytic-predictive use of historical variance data for the design and analysis of clinical trials, Computational Statistics & Data Analysis, 10.1016/j.csda.2016.08.007, 113, (100-110), (2017).
- Jan O. Jansen, Philip Pallmann, Graeme MacLennan, Marion K. Campbell, Bayesian clinical trial designs, Journal of Trauma and Acute Care Surgery, 10.1097/TA.0000000000001638, 83, 4, (736-741), (2017).
- Konrad Neumann, Ulrike Grittner, Sophie K. Piper, Andre Rex, Oscar Florez-Vargas, George Karystianis, Alice Schneider, Ian Wellwood, Bob Siegerink, John P. A. Ioannidis, Jonathan Kimmelman, Ulrich Dirnagl, Increasing efficiency of preclinical research by group sequential designs, PLOS Biology, 10.1371/journal.pbio.2001307, 15, 3, (e2001307), (2017).
- Anja Bertsche, Frank Fleischer, Jan Beyersmann, Gerhard Nehmiz, Bayesian Phase II optimization for time-to-event data based on historical information, Statistical Methods in Medical Research, 10.1177/0962280217747310, (096228021774731), (2017).
- Caroline Brard, Gwénaël Le Teuff, Marie-Cécile Le Deley, Lisa V Hampson, Bayesian survival analysis in clinical trials: What methods are used in practice?, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774516673362, 14, 1, (78-87), (2016).
- Andrew P. Grieve, Idle thoughts of a ‘well‐calibrated’ Bayesian in clinical drug development, Pharmaceutical Statistics, 10.1002/pst.1736, 15, 2, (96-108), (2016).
- Andreia Leite, Nick J. Andrews, Sara L. Thomas, Near real‐time vaccine safety surveillance using electronic health records—a systematic review of the application of statistical methods , Pharmacoepidemiology and Drug Safety, 10.1002/pds.3966, 25, 3, (225-237), (2016).
- Roland Fisch, Ieuan Jones, Julie Jones, Jouni Kerman, Gerd Karl Rosenkranz, Heinz Schmidli, Bayesian Design of Proof-of-Concept Trials, Therapeutic Innovation & Regulatory Science, 10.1177/2168479014533970, 49, 1, (155-162), (2014).




